Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1995-2-27
|
pubmed:abstractText |
To investigate the possibility of correcting thrombocytopenia of chronic liver disease, 19 patients (6 male and 13 female) with long-term chronic liver disease and platelet count < or = 85,000/microliters were studied. Either a short-term course (7-20 days) of recombinant human erythropoietin, 4000 U daily SQ (12 patients) or placebo (7 patients) was administered. Treatment was interrupted if the platelets rose to > or = 100,000/microliters or if no significant increase was noted after 14 days. After treatment, platelets increased in the recombinant human erythropoietin group (from a baseline value of 70,000 +/- 11,184 to 101,250 +/- 37,625/microliters), while no difference was noted in the placebo group (70,714 +/- 9928 vs 70,000 +/- 10,231/microliters). The increase in the platelet count in the recombinant human erythropoietin group was significant, both compared to baseline values (paired Student's t-test, t = -3.80, p < 0.005) and to the results of treatment in the placebo group (unpaired Student's t-test, t = 2.71, p < 0.02). Eight out of 12 recombinant human erythropoietin-treated patients (66%) reached > or = 100,000/microliters platelets while four (33%) did not. In comparison to responders, non-responders had a significantly lower baseline platelet count (58,500 +/- 7937 vs 75,750 +/- 7498/microliters, t = -3.69, p = 0.004) and failed more frequently than responders to improve their haematocrit in response to recombinant human erythropoietin (Pearson chi 2 = 4.687, p = 0.03). When treatment was discontinued, the platelet count reverted to baseline in a few weeks. In conclusion, recombinant human erythropoietin treatment transiently corrected mild thrombocytopenia in patients with chronic liver disease.(ABSTRACT TRUNCATED AT 250 WORDS)
|
pubmed:commentsCorrections | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
0168-8278
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
21
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
376-80
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:7836707-Aged,
pubmed-meshheading:7836707-Blood Platelets,
pubmed-meshheading:7836707-Chronic Disease,
pubmed-meshheading:7836707-Dose-Response Relationship, Drug,
pubmed-meshheading:7836707-Erythropoietin,
pubmed-meshheading:7836707-Female,
pubmed-meshheading:7836707-Humans,
pubmed-meshheading:7836707-Liver Diseases,
pubmed-meshheading:7836707-Male,
pubmed-meshheading:7836707-Middle Aged,
pubmed-meshheading:7836707-Recombinant Proteins,
pubmed-meshheading:7836707-Thrombocytopenia
|
pubmed:year |
1994
|
pubmed:articleTitle |
Thrombocytopenia of chronic liver disease corrected by erythropoietin treatment.
|
pubmed:affiliation |
Cattedra di Medicina Interna, Università degli Studi, Udine, Italy.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Controlled Clinical Trial
|